Literature DB >> 7982658

Phenobarbital induction of alpha 1-acid glycoprotein in primary rat hepatocyte cultures.

T Fournier1, N Mejdoubi, D Monnet, G Durand, D Porquet.   

Abstract

The serum level of rat alpha 1-acid glycoprotein is significantly increased by treatment with phenobarbital, and in vivo studies have shown that phenobarbital seems to act mainly at the transcriptional level. To show the direct mediating effect of phenobarbital on alpha 1-acid glycoprotein gene expression, we investigated the ability of primary cultured rat hepatocytes to respond to in vitro phenobarbital administration. Phenobarbital increased both alpha 1 acid glycoprotein secretion and corresponding mRNA levels in primary rat hepatocytes cultured on matrigel. Used in combination with interleukin-1, interleukin-6 and dexamethasone, phenobarbital had an additive or synergistic effect on alpha 1-acid glycoprotein synthesis. These results show that (a) phenobarbital acts directly on hepatocytes by increasing alpha 1-acid glycoprotein gene expression and (b) this effect is mediated by a specific mechanism independent of pathways involved in alpha 1-acid glycoprotein induction by interleukin-1, interleukin-6 and glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982658     DOI: 10.1002/hep.1840200630

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Effects of insulin, dexamethasone and cytokines on alpha 1-acid glycoprotein gene expression in primary cultures of normal rat hepatocytes.

Authors:  B Barraud; S Balavoine; G Feldmann; B Lardeux
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

2.  Lipophilicity Influences Drug Binding to α1-Acid Glycoprotein F1/S Variants But Not to the A Variant.

Authors:  Kazuhiko Hanada
Journal:  Drugs R D       Date:  2017-09

3.  Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs.

Authors:  Claudia Ottka; Corinna Weber; Elisabeth Müller; Hannes Lohi
Journal:  Metabolomics       Date:  2021-06-02       Impact factor: 4.290

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.